NCT04088123

Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects

Investigation of Anti-platelet Drug Single Dose Exposure on Platelet mRNA Splicing in Healthy Subjects

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: George Washington University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: —

Summary

The purpose of this pilot study is to determine how the anti-platelet drug, ticagrelor, impacts platelet mRNA splicing after a single loading dose in 10 healthy participants. These results will be valuable in that they will help inform our analysis of platelet RNA splicing after a thrombotic event.

Detailed description

There is nothing known on how differential splicing in platelets is impacted by of P2Y12 inhibition by anti-platelet agents. Consequently, the focus of this longitudinal pilot study will be to determine the impact of a single ticagrelor loading dose (180 mg), our "model" anti-platelet drug, on platelet RNA splicing in 10 healthy individuals. It will test the hypothesis that ticagrelor exposure does not significantly alter platelet mRNA splicing. It will involve administering a single loading dose (180 mg) of ticagrelor to healthy volunteers.

Conditions

• Thrombosis; Artery

Interventions

Type	Name	Description
DRUG	Ticagrelor Oral Tablet [Brilinta]	A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.

Timeline

• Start date: 2020-04-01
• Primary completion: 2020-09-23
• Completion: 2020-09-23
• First posted: 2019-09-12
• Last updated: 2021-10-28

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study